Unidym brings to this partnership its leadership in carbon nanotube science, technology and production. PrimeGen will have access to Unidym’s extensive patent portfolio, services and industry standard Hipco carbon nanotubes. PrimeGen previously said that, researchers have, for the first time, successfully used non-viral technologies to reprogram adult human cells into stem cells that the company refers to as intermediate iPS cells.
Thomas Yuen, CEO of PrimeGen Biotech, said: “Our combined efforts will undoubtedly generate important advances in the field of regenerative medicine and bring us closer to the day when clinically safe and effective individualized stem cell therapies can be administered in a routine manner to patients.”